| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
HCV NS3; GLUT4
Sennidin B targets similar pathways to Sennidin A, including the PI3K/Akt signaling pathway and glucose transporters (GLUT4). It induces phosphorylation of Akt and GLUT4 translocation, stimulating glucose incorporation. However, it has lower activity than Sennidin A. The compound is also a substrate for bacterial hydrolysis of sennosides. |
|---|---|
| ln Vitro |
In vitro, Sennidin B stimulates glucose incorporation and induces phosphorylation of Akt and GLUT4 translocation. However, it has lower activity than Sennidin A. The compound is a stereoisomer with similar but reduced biological effects compared to its counterpart.
|
| ln Vivo |
Sennidin B has lower in vivo activity than Sennidin A. It is primarily studied for its role as a laxative, aiding in gastrointestinal motility by stimulating the colon's smooth muscles. The compound also exhibits potential antioxidant and anti-inflammatory properties. Further in vivo studies are needed to fully characterize its pharmacological effects.
|
| Enzyme Assay |
For in vitro enzyme inhibition assays, Sennidin B can be tested against HCV NS3 helicase, although it has lower activity than Sennidin A. The helicase enzyme is incubated with varying concentrations of the compound and a substrate in the presence of ATP. Helicase activity is measured by monitoring substrate unwinding. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, Sennidin B is typically tested on adipocytes. Cells are treated with the compound at various concentrations (typically 1-100 μM) and glucose uptake is measured using 2-deoxyglucose uptake assays. Phosphorylation of Akt and GLUT4 translocation are assessed by Western blotting. The activity is compared to Sennidin A to determine relative potency.
|
| Animal Protocol |
In vivo animal experiments for Sennidin B have not been extensively reported. Based on its role as a laxative, potential experimental models include constipation models in mice or rats. The compound could be administered orally, and gastrointestinal motility would be assessed as a pharmacodynamic endpoint. Antioxidant and anti-inflammatory activities could be evaluated in appropriate disease models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Sennidin B are limited. As a dimeric anthraquinone with a molecular weight of 538.46 g/mol and formula C₃₀H₁₈O₁₀, it is expected to have moderate oral bioavailability. The compound is formed from sennosides by bacterial hydrolysis in the intestine. Standard pharmacokinetic studies would be required to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Sennidin B are limited. As a natural anthraquinone, it may have cytotoxic effects at high concentrations. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human use.
|
| References | |
| Additional Infomation |
Sennoside B belongs to the anthracene class of compounds. It has been reported that senna leaves contain sennoside B, and relevant data are available for reference.
Sennidin B is a research-use only compound and has not been approved for clinical applications. It is also known as番泻苷元B in Chinese. The compound is a stereoisomer of Sennidin A isolated from Cassia angustifolia. Its molecular weight is 538.46 and formula is C₃₀H₁₈O₁₀. It is available from various research chemical suppliers. |
| Molecular Formula |
C30H18O10
|
|---|---|
| Molecular Weight |
538.4579
|
| Exact Mass |
538.09
|
| CAS # |
517-44-2
|
| Related CAS # |
Sennidin A; 641-12-3
|
| PubChem CID |
10459879
|
| Appearance |
Yellow to brown solid
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
801.8±65.0 °C at 760 mmHg
|
| Flash Point |
452.6±30.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.806
|
| LogP |
8.24
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
40
|
| Complexity |
977
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C1C2C(=C([H])C([H])=C([H])C=2[C@@]([H])(C2C([H])=C(C(=O)O[H])C([H])=C(C=21)O[H])[C@]1([H])C2C([H])=C([H])C([H])=C(C=2C(C2C(=C([H])C(C(=O)O[H])=C([H])C1=2)O[H])=O)O[H])O[H]
|
| InChi Key |
JPMRHWLJLNKRTJ-SZPZYZBQSA-N
|
| InChi Code |
InChI=1S/C30H18O10/c31-17-5-1-3-13-21(15-7-11(29(37)38)9-19(33)25(15)27(35)23(13)17)22-14-4-2-6-18(32)24(14)28(36)26-16(22)8-12(30(39)40)10-20(26)34/h1-10,21-22,31-34H,(H,37,38)(H,39,40)/t21-,22+
|
| Chemical Name |
(9S)-9-[(9R)-2-carboxy-4,5-dihydroxy-10-oxo-9H-anthracen-9-yl]-4,5-dihydroxy-10-oxo-9H-anthracene-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~92.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8571 mL | 9.2857 mL | 18.5715 mL | |
| 5 mM | 0.3714 mL | 1.8571 mL | 3.7143 mL | |
| 10 mM | 0.1857 mL | 0.9286 mL | 1.8571 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
